Compare iShares Core Growth Allocation ETF (AOR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Neurocrine Biosciences Inc — how do they compare? iShares Core Growth Allocation ETF trades at $69.09, while Neurocrine Biosciences Inc trades at $179.72 (market cap $17.82B). Which is the better fit depends on your goals.
| AOR | NBIX | |
|---|---|---|
52-Week High | $69.85 | $180.55 |
52-Week Low | $61.00 | $123.10 |
Market Cap | — | $17.82B |
Sector | — | Health |
Enterprise Value | — | $16.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares Core Growth Allocation ETF (AOR) trades at $69.10, up 0.25% on the day, with a bearish technical signal from moving averages and neutral oscillators. The fund maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low 0.20% expense ratio. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
Outlook: AOR offers diversified, low-cost exposure but faces headwinds from equity-bond correlation shifts. Risks include interest rate sensitivity and competition from pure equity funds. Analyst sentiment is mixed, balancing simplicity against relative returns.
Neurocrine Biosciences (NBIX) trades at $177.11, down 1.91% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical signal with moving averages supporting upward trends, while RSI levels indicate potential overbought conditions. Recent news highlights strong sales growth from Ingrezza and pipeline advancements, including the Soleno acquisition, reinforcing long-term growth prospects in neuroscience.
Outlook remains positive with a consensus price target of $194, offering ~9.5% upside. Key opportunities include expanding product portfolio and blockbuster drug performance, while risks involve pipeline execution and market volatility. The stock's high valuation multiples require sustained growth to justify current levels, but analyst sentiment is overwhelmingly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
